Piracetam for acute ischaemic stroke

Ricci S, Celani MG, Cantisani TA, Righetti E

Published Online:

July 8, 2009

Ischaemic stroke is the third leading cause of death in developed countries, and the first leading cause of long-term disability in survivors. Piracetam is a drug which has been marketed by drug companies in several countries for many years as a 'nootropic' agent: a drug which has metabolic activity in the human brain. The efficacy and safety of piracetam in patients with acute stroke have not yet been proven. Experiments in animals suggest that piracetam could have beneficial effects in patients with acute stroke. There have been a number of randomised controlled trials of piracetam given to patients within 48 hours of the onset of their stroke. Data from three trials, involving 1002 patients, were available for this review, but almost all came from a single study. The data reviewed did not provide conclusive evidence about the effects of piracetam for acute stroke. One additional, large study has been conducted and interrupted by the manufacturer after some preliminary analyses were carried out, but the results have not been made available to the scientific community.

Abstract (click to read)

Background:

Piracetam has neuroprotective and antithrombotic effects that may help to reduce death and disability in people with acute stroke. This is an update of a Cochrane Review first published in 1999, and previously updated in 2006.

Objectives:

To assess the effects of piracetam in acute, presumed ischaemic stroke.

Search strategy:

We searched the Cochrane Stroke Group Trials Register (last searched 24 October 2008), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library Issue 4, 2008), MEDLINE (1966 to October 2008), EMBASE (1980 to October 2008), and ISI Science Citation Index (1981 to October 2008). We also contacted the manufacturer of piracetam to identify further published and unpublished studies.

Selection criteria:

Randomised trials comparing piracetam with control, with at least mortality reported and entry to the trial within approximately 48 hours of stroke onset.

Data collection and analysis:

Two review authors extracted data and assessed trial quality and this was checked by the other two review authors. We contacted study authors for missing information.

Main results:

We included three trials involving 1002 patients, with one trial contributing 93% of the data. Participants' ages ranged from 40 to 85, and both sexes were equally represented. Piracetam was associated with a statistically non-significant increase in death at one month (approximately 31% increase, 95% confidence interval 81% increase to 5% reduction). This trend was no longer apparent in the large trial after correction for imbalance in stroke severity. Limited data showed no difference between the treatment and control groups for functional outcome, dependency or proportion of patients dead or dependent. Adverse effects were not reported.

Authors' conclusions:

There is some suggestion (but no statistically significant result) of an unfavourable effect of piracetam on early death, but this may have been caused by baseline differences in stroke severity in the trials. There is not enough evidence to assess the effect of piracetam on dependency.

This record should be cited as:

Ricci S, Celani MG, Cantisani TA, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD000419. DOI: 10.1002/14651858.CD000419.pub2

Assessed as up to date:

October 24, 2008

Find the research

Get full text at The Cochrane Library

Primary Review Group:

Stroke Group

Health topics:

Heart & circulation > Stroke > Ischemic stroke/TIA: treatment

Neurology > Stroke > Ischemic stroke/TIA: treatment

Cochrane Summaries^beta

Independent high-quality evidence for health care decision making

Piracetam for acute ischaemic stroke

More like this

Copyright © 2012 - The Cochrane Collaboration